

Joseph R Testa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7803965/publications.pdf>

Version: 2024-02-01

161
papers

13,657
citations

26567

56
h-index

24915

109
g-index

169
all docs

169
docs citations

169
times ranked

16301
citing authors

#	ARTICLE	IF	CITATIONS
1	Inactivation of p21-Activated Kinase 2 (Pak2) Inhibits the Development of <i>Nf2</i> -Deficient Tumors by Restricting Downstream Hedgehog and Wnt Signaling. <i>Molecular Cancer Research</i> , 2022, 20, 699-711.	1.5	6
2	Asbestos and Other Hazardous Fibrous Minerals: Potential Exposure Pathways and Associated Health Risks. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 4031.	1.2	16
3	Mesothelioma Mouse Models with Mixed Genomic States of Chromosome and Microsatellite Instability. <i>Cancers</i> , 2022, 14, 3108.	1.7	4
4	Somatic Epigenetic Silencing of <i>RIPK3</i> Inactivates Necroptosis and Contributes to Chemoresistance in Malignant Mesothelioma. <i>Clinical Cancer Research</i> , 2021, 27, 1200-1213.	3.2	26
5	Kinetic Characterization of ASXL1/2-Mediated Allosteric Regulation of the BAP1 Deubiquitinase. <i>Molecular Cancer Research</i> , 2021, 19, 1099-1112.	1.5	1
6	Novel <i>LRRK2</i> mutations and other rare, non- <i>BAP1</i> -related candidate tumor predisposition gene variants in high-risk cancer families with mesothelioma and other tumors. <i>Human Molecular Genetics</i> , 2021, 30, 1750-1761.	1.4	7
7	DLX Genes: Roles in Development and Cancer. <i>Cancers</i> , 2021, 13, 3005.	1.7	27
8	Application of Chromosome Microarray Analysis for the Differential Diagnosis of Low-grade Renal Cell Carcinoma With Clear Cell and Papillary Features. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2020, 28, 123-129.	0.6	4
9	Monosomy of Chromosome 9 Is Associated With Higher Grade, Advanced Stage, and Adverse Outcome in Clear-cell Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 56-61.	0.9	4
10	Hypomorphic mTOR Downregulates CDK6 and Delays Thymic Pre-T LBL Tumorigenesis. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2221-2232.	1.9	7
11	Wnt signaling mediates oncogenic synergy between Akt and <i>Dlx5</i> in T-cell lymphomagenesis by enhancing cholesterol synthesis. <i>Scientific Reports</i> , 2020, 10, 15837.	1.6	6
12	BRCA1 Mutational Complementation Induces Synthetic Viability. <i>Molecular Cell</i> , 2020, 78, 951-959.e6.	4.5	41
13	Overall tumor genomic instability: an important predictor of recurrence-free survival in patients with localized clear cell renal cell carcinoma. <i>Cancer Biology and Therapy</i> , 2020, 21, 424-431.	1.5	8
14	Challenging Global Waste Management – Bioremediation to Detoxify Asbestos. <i>Frontiers in Environmental Science</i> , 2020, 8, .	1.5	17
15	Preclinical Models of Malignant Mesothelioma. <i>Frontiers in Oncology</i> , 2020, 10, 101.	1.3	19
16	RPL22L1 induction in colorectal cancer is associated with poor prognosis and 5-FU resistance. <i>PLoS ONE</i> , 2019, 14, e0222392.	1.1	19
17	Thymine DNA glycosylase as a novel target for melanoma. <i>Oncogene</i> , 2019, 38, 3710-3728.	2.6	28
18	Inactivation of <i>Bap1</i> Cooperates with Losses of <i>Nf2</i> and <i>Cdkn2a</i> to Drive the Development of Pleural Malignant Mesothelioma in Conditional Mouse Models. <i>Cancer Research</i> , 2019, 79, 4113-4123.	0.4	42

#	ARTICLE	IF	CITATIONS
19	Detecting MYB and MYBL1 fusion genes in tracheobronchial adenoid cystic carcinoma by targeted RNA-sequencing. <i>Modern Pathology</i> , 2019, 32, 1416-1420.	2.9	26
20	PBRM1 acts as a p53 lysine-acetylation reader to suppress renal tumor growth. <i>Nature Communications</i> , 2019, 10, 5800.	5.8	47
21	Clinical application of RNA sequencing in sarcoma diagnosis. <i>Medicine (United States)</i> , 2019, 98, e16031.	0.4	24
22	NEAT1-TFE3 and KAT6A-TFE3 renal cell carcinomas, new members of MiT family translocation renal cell carcinoma. <i>Modern Pathology</i> , 2019, 32, 710-716.	2.9	54
23	The correlation between gain of chromosome 8q and survival in patients with clear and papillary renal cell carcinoma. <i>Therapeutic Advances in Urology</i> , 2018, 10, 3-10.	0.9	3
24	Familial and Somatic <i>BAP1</i> Mutations Inactivate ASXL1/2-Mediated Allosteric Regulation of BAP1 Deubiquitinase by Targeting Multiple Independent Domains. <i>Cancer Research</i> , 2018, 78, 1200-1213.	0.4	24
25	Malignant Mesothelioma. <i>Atlas of Genetics and Cytogenetics in Oncology and Haematology</i> , 2018, , .	0.1	1
26	Comprehensive Study of the Clinical Phenotype of Germline <i>BAP1</i> Variant-Carrying Families Worldwide. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1328-1341.	3.0	164
27	BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance. <i>Cell Reports</i> , 2018, 24, 3513-3527.e7.	2.9	61
28	Inactivation of <i>p53</i> and <i>Pten</i> drives rapid development of pleural and peritoneal malignant mesotheliomas. <i>Journal of Cellular Physiology</i> , 2018, 233, 8952-8961.	2.0	20
29	Multiple tumor suppressors regulate a HIF-dependent negative feedback loop via ISGF3 in human clear cell renal cancer. <i>ELife</i> , 2018, 7, .	2.8	25
30	Malignant Mesothelioma: An Asbestos Legacy. <i>Current Cancer Research</i> , 2017, , 1-9.	0.2	1
31	BAP1, a tumor suppressor gene driving malignant mesothelioma. <i>Translational Lung Cancer Research</i> , 2017, 6, 270-278.	1.3	54
32	Germline and Somatic Mutations in Human Mesothelioma and Lessons from Asbestos-Exposed Genetically Engineered Mouse Models. <i>Current Cancer Research</i> , 2017, , 175-195.	0.2	3
33	Haploinsufficiency in tumor predisposition syndromes: altered genomic transcription in morphologically normal cells heterozygous for <i>VHL</i> or <i>TSC</i> mutation. <i>Oncotarget</i> , 2017, 8, 17628-17642.	0.8	11
34	The homeoprotein <i>Dlx5</i> drives murine T-cell lymphomagenesis by directly transactivating Notch and upregulating Akt signaling. <i>Oncotarget</i> , 2017, 8, 14941-14956.	0.8	9
35	Intratumor heterogeneity analysis reveals hidden associations between protein expression losses and patient survival in clear cell renal cell carcinoma. <i>Oncotarget</i> , 2017, 8, 37423-37434.	0.8	16
36	Targeting MYC sensitizes malignant mesothelioma cells to PAK blockage-induced cytotoxicity. <i>American Journal of Cancer Research</i> , 2017, 7, 1724-1737.	1.4	8

#	ARTICLE	IF	CITATIONS
37	Immunohistochemistry Successfully Uncovers Intratumoral Heterogeneity and Widespread Co-Losses of Chromatin Regulators in Clear Cell Renal Cell Carcinoma. <i>PLoS ONE</i> , 2016, 11, e0164554.	1.1	19
38	Ribosomal Protein Rpl22 Controls the Dissemination of T-cell Lymphoma. <i>Cancer Research</i> , 2016, 76, 3387-3396.	0.4	24
39	Genomic Copy Number Alterations in Renal Cell Carcinoma with Sarcomatoid Features. <i>Journal of Urology</i> , 2016, 195, 852-858.	0.2	22
40	Genomic imbalances in peripheral blood confirm the diagnosis of myelodysplastic syndrome in a patient presenting with non-immune hemolytic anemia. <i>Leukemia Research Reports</i> , 2016, 5, 23-26.	0.2	5
41	Appl1 and Appl2 are Expendable for Mouse Development But Are Essential for HGF-Induced Akt Activation and Migration in Mouse Embryonic Fibroblasts. <i>Journal of Cellular Physiology</i> , 2016, 231, 1142-1150.	2.0	13
42	Germline BAP1 Mutational Landscape of Asbestos-Exposed Malignant Mesothelioma Patients with Family History of Cancer. <i>Cancer Research</i> , 2016, 76, 206-215.	0.4	93
43	Flaxseed lignans enriched in secoisolariciresinol diglucoside prevent acute asbestos-induced peritoneal inflammation in mice. <i>Carcinogenesis</i> , 2016, 37, 177-187.	1.3	44
44	Bap1 Is a Bona Fide Tumor Suppressor: Genetic Evidence from Mouse Models Carrying Heterozygous Germline <i>Bap1</i> Mutations. <i>Cancer Research</i> , 2016, 76, 2836-2844.	0.4	95
45	Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration. <i>Cancer Biology and Therapy</i> , 2016, 17, 328-335.	1.5	47
46	Inflammation-Related IL1 β /IL1R Signaling Promotes the Development of Asbestos-Induced Malignant Mesothelioma. <i>Cancer Prevention Research</i> , 2016, 9, 406-414.	0.7	68
47	SWOG S0722: Phase II Study of mTOR Inhibitor Everolimus (RAD001) in Advanced Malignant Pleural Mesothelioma (MPM). <i>Journal of Thoracic Oncology</i> , 2015, 10, 387-391.	0.5	67
48	Inhibition of mesothelioma cancer stem-like cells with adenovirus-mediated <i>NK4</i> gene therapy. <i>International Journal of Cancer</i> , 2015, 137, 481-490.	2.3	13
49	Disregulated expression of the transcription factor ThPOK during T-cell development leads to high incidence of T-cell lymphomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 7773-7778.	3.3	18
50	Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary. <i>Molecular Cancer Research</i> , 2015, 13, 795-806.	1.5	25
51	Constitutively Active Akt1 Cooperates with KRasG12D to Accelerate In Vivo Pancreatic Tumor Onset and Progression. <i>Neoplasia</i> , 2015, 17, 175-182.	2.3	26
52	Co-targeting of Akt and Myc inhibits viability of lymphoma cells from Lck-Dlx5 mice. <i>Cancer Biology and Therapy</i> , 2015, 16, 580-588.	1.5	16
53	Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma. <i>BMC Cancer</i> , 2015, 15, 376.	1.1	22
54	The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer. <i>Cancer Genetics</i> , 2015, 208, 206-214.	0.2	48

#	ARTICLE	IF	CITATIONS
55	Germline BAP1 mutation in a family with high incidence of multiple primary cancers and a potential gene-environment interaction. <i>Cancer Letters</i> , 2015, 369, 261-265.	3.2	42
56	An asbestos-exposed family with multiple cases of pleural malignant mesothelioma without inheritance of a predisposing BAP1 mutation. <i>Cancer Genetics</i> , 2015, 208, 502-507.	0.2	13
57	Merlin Deficiency Predicts FAK Inhibitor Sensitivity: A Synthetic Lethal Relationship. <i>Science Translational Medicine</i> , 2014, 6, 237ra68.	5.8	203
58	Germline Mutation of <i>Bap1</i> Accelerates Development of Asbestos-Induced Malignant Mesothelioma. <i>Cancer Research</i> , 2014, 74, 4388-4397.	0.4	129
59	Molecular Cytogenetic Analysis of the Scleractinian Coral <i>Acropora solitaryensis</i> Veron & Wallace 1984. <i>Zoological Science</i> , 2014, 31, 89-94.	0.3	12
60	Copy neutral loss of heterozygosity in 20q in chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Cancer Genetics</i> , 2014, 207, 98-102.	0.2	11
61	Tumor Suppressor Alterations Cooperate to Drive Aggressive Mesotheliomas with Enriched Cancer Stem Cells via a p53-miR-34a-c-Met Axis. <i>Cancer Research</i> , 2014, 74, 1261-1271.	0.4	55
62	Further evidence for germline BAP1 mutations predisposing to melanoma and malignant mesothelioma. <i>Cancer Genetics</i> , 2013, 206, 206-210.	0.2	81
63	BAP1 and cancer. <i>Nature Reviews Cancer</i> , 2013, 13, 153-159.	12.8	522
64	NF- κ B Inhibition by Bortezomib Permits IFN- γ -Activated RIP1 Kinase-Dependent Necrosis in Renal Cell Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 1568-1578.	1.9	17
65	Potential Role of mTORC2 as a Therapeutic Target in Clear Cell Carcinoma of the Ovary. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 1367-1377.	1.9	41
66	Cancer stem-like cell properties are regulated by EGFR/AKT/ β -catenin signaling and preferentially inhibited by gefitinib in nasopharyngeal carcinoma. <i>FEBS Journal</i> , 2013, 280, 2027-2041.	2.2	81
67	Connecting Molecular Pathways to Hereditary Cancer Risk Syndromes. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , 81-90.	1.8	14
68	Connecting Molecular Pathways to Hereditary Cancer Risk Syndromes. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, 81-90.	1.8	19
69	Diverse Mechanisms of AKT Pathway Activation in Human Malignancy. <i>Current Cancer Drug Targets</i> , 2013, 13, 234-244.	0.8	156
70	Increasing the therapeutic index of 5-fluorouracil and 6-thioguanine by targeting loss of MTAP in tumor cells. <i>Cancer Biology and Therapy</i> , 2012, 13, 1082-1090.	1.5	25
71	Identification of Akt Interaction Protein PHF20/TZP That Transcriptionally Regulates p53. <i>Journal of Biological Chemistry</i> , 2012, 287, 11151-11163.	1.6	27
72	Inactivation of ribosomal protein L22 promotes transformation by induction of the stemness factor, Lin28B. <i>Blood</i> , 2012, 120, 3764-3773.	0.6	132

#	ARTICLE	IF	CITATIONS
73	CD45-deficient severe combined immunodeficiency caused by uniparental disomy. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 10456-10461.	3.3	39
74	Chromothripsis in a case of TP53-deficient chronic lymphocytic leukemia. Leukemia Research Reports, 2012, 1, 4-6.	0.2	12
75	Group I p21-Activated Kinases (PAKs) Promote Tumor Cell Proliferation and Survival through the AKT1 and Rafâ€“MAPK Pathways. Molecular Cancer Research, 2012, 10, 1178-1188.	1.5	42
76	Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome. Genes Chromosomes and Cancer, 2011, 50, 606-618.	1.5	90
77	ERK2 is essential for the growth of human epithelioid malignant mesotheliomas. International Journal of Cancer, 2011, 129, 1075-1086.	2.3	38
78	An Extracellular Signalâ€“Regulated Kinase 2 Survival Pathway Mediates Resistance of Human Mesothelioma Cells to Asbestos-Induced Injury. American Journal of Respiratory Cell and Molecular Biology, 2011, 45, 906-914.	1.4	14
79	Germline BAP1 mutations predispose to malignant mesothelioma. Nature Genetics, 2011, 43, 1022-1025.	9.4	924
80	Factors that Impact Susceptibility to Fiber-Induced Health Effects. Journal of Toxicology and Environmental Health - Part B: Critical Reviews, 2011, 14, 246-266.	2.9	19
81	Pten mediates Myc oncogene dependence in a conditional zebrafish model of T cell acute lymphoblastic leukemia. Journal of Experimental Medicine, 2011, 208, 1595-1603.	4.2	104
82	Losses of Both Products of the Cdkn2a/Arf Locus Contribute to Asbestos-Induced Mesothelioma Development and Cooperate to Accelerate Tumorigenesis. PLoS ONE, 2011, 6, e18828.	1.1	59
83	Onconase responsive genes in human mesothelioma cells: implications for an RNA damaging therapeutic agent. BMC Cancer, 2010, 10, 34.	1.1	29
84	Genetic Dissection of the Oncogenic mTOR Pathway Reveals Druggable Addiction to Translational Control via 4EBP-eIF4E. Cancer Cell, 2010, 17, 249-261.	7.7	420
85	T-Lymphoblastic Lymphoma Cells Express High Levels of BCL2, S1P1, and ICAM1, Leading to a Blockade of Tumor Cell Intravasation. Cancer Cell, 2010, 18, 353-366.	7.7	141
86	Combined classical cytogenetics and microarrayâ€“based genomic copy number analysis reveal frequent 3;5 rearrangements in clear cell renal cell carcinoma. Genes Chromosomes and Cancer, 2010, 49, 610-619.	1.5	22
87	The biology of ovarian cancer development. Cancer, 2010, 71, 530-536.	2.0	91
88	Appl1 is dispensable for Akt signaling in vivo and mouse Tâ€“cell development. Genesis, 2010, 48, 531-539.	0.8	15
89	Inflammation precedes the development of human malignant mesotheliomas in a SCID mouse xenograft model. Annals of the New York Academy of Sciences, 2010, 1203, 7-14.	1.8	74
90	Vascular Endothelial Growth Factor Is a Promising Therapeutic Target for the Treatment of Clear Cell Carcinoma of the Ovary. Molecular Cancer Therapeutics, 2010, 9, 2411-2422.	1.9	76

#	ARTICLE	IF	CITATIONS
91	Appl1 Is Dispensable for Mouse Development, and Loss of Appl1 Has Growth Factor-selective Effects on Akt Signaling in Murine Embryonic Fibroblasts. <i>Journal of Biological Chemistry</i> , 2010, 285, 6377-6389.	1.6	49
92	Upregulation of DLX5 Promotes Ovarian Cancer Cell Proliferation by Enhancing IRS-2-AKT Signaling. <i>Cancer Research</i> , 2010, 70, 9197-9206.	0.4	49
93	A Phosphotyrosine Proteomic Screen Identifies Multiple Tyrosine Kinase Signaling Pathways Aberrantly Activated in Malignant Mesothelioma. <i>Genes and Cancer</i> , 2010, 1, 493-505.	0.6	48
94	Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin. <i>Molecular Cancer</i> , 2010, 9, 314.	7.9	64
95	GSK690693 Delays Tumor Onset and Progression in Genetically Defined Mouse Models Expressing Activated Akt. <i>Clinical Cancer Research</i> , 2010, 16, 486-496.	3.2	49
96	FAS-Associated Factor 1 (FAF1): Diverse functions and implications for oncogenesis. <i>Cell Cycle</i> , 2009, 8, 2528-2534.	1.3	80
97	Loss of GATA6 Leads to Nuclear Deformation and Aneuploidy in Ovarian Cancer. <i>Molecular and Cellular Biology</i> , 2009, 29, 4766-4777.	1.1	56
98	mTOR Is a Promising Therapeutic Target Both in Cisplatin-Sensitive and Cisplatin-Resistant Clear Cell Carcinoma of the Ovary. <i>Clinical Cancer Research</i> , 2009, 15, 5404-5413.	3.2	151
99	Activated TNF- α /NF- κ B signaling via down-regulation of Fas-associated factor 1 in asbestos-induced mesotheliomas from <i>Arf</i> knockout mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 3420-3425.	3.3	69
100	DLX5 (Distal-less Homeobox 5) Promotes Tumor Cell Proliferation by Transcriptionally Regulating MYC. <i>Journal of Biological Chemistry</i> , 2009, 284, 20593-20601.	1.6	41
101	Genomic events associated with progression of pleural malignant mesothelioma. <i>International Journal of Cancer</i> , 2009, 124, 589-599.	2.3	67
102	Recurrent chromosomal rearrangements implicate oncogenes contributing to T-cell lymphomagenesis in Lck-MyrAkt2 transgenic mice. <i>Genes Chromosomes and Cancer</i> , 2009, 48, 786-794.	1.5	16
103	High density DNA array analysis reveals distinct genomic profiles in a subset of gastrointestinal stromal tumors. <i>Genes Chromosomes and Cancer</i> , 2009, 48, 886-896.	1.5	37
104	Activated cAMP Response Element Binding Protein Is Overexpressed in Human Mesotheliomas and Inhibits Apoptosis. <i>American Journal of Pathology</i> , 2009, 175, 2197-2206.	1.9	43
105	Mesothelioma Epidemiology, Carcinogenesis, and Pathogenesis. <i>Current Treatment Options in Oncology</i> , 2008, 9, 147-157.	1.3	207
106	A Novel Recurrent Chromosomal Inversion Implicates the Homeobox Gene <i>Dlx5</i> in T-Cell Lymphomas from Lck-Akt2 Transgenic Mice. <i>Cancer Research</i> , 2008, 68, 1296-1302.	0.4	31
107	HGF Mediates Cell Proliferation of Human Mesothelioma Cells through a PI3K/MEK5/Fra-1 Pathway. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2008, 38, 209-217.	1.4	63
108	Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 8387-8392.	3.3	225

#	ARTICLE	IF	CITATIONS
109	A Novel Mechanism of Late Gene Silencing Drives SV40 Transformation of Human Mesothelial Cells. <i>Cancer Research</i> , 2008, 68, 9488-9496.	0.4	27
110	Whole-Genome Profiling in Liposarcomas Reveals Genetic Alterations Common to Specific Telomere Maintenance Mechanisms. <i>Cancer Research</i> , 2007, 67, 9221-9228.	0.4	20
111	RAD001 (Everolimus) Delays Tumor Onset and Progression in a Transgenic Mouse Model of Ovarian Cancer. <i>Cancer Research</i> , 2007, 67, 2408-2413.	0.4	178
112	Phase II Study of Erlotinib in Patients With Malignant Pleural Mesothelioma: A Southwest Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2007, 25, 2406-2413.	0.8	219
113	RAD001 Inhibits Human Ovarian Cancer Cell Proliferation, Enhances Cisplatin-Induced Apoptosis, and Prolongs Survival in an Ovarian Cancer Model. <i>Clinical Cancer Research</i> , 2007, 13, 4261-4270.	3.2	216
114	APPL1 Associates with TrkA and GIPC1 and Is Required for Nerve Growth Factor-Mediated Signal Transduction. <i>Molecular and Cellular Biology</i> , 2006, 26, 8928-8941.	1.1	137
115	TNF- α inhibits asbestos-induced cytotoxicity via a NF- κ B-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 10397-10402.	3.3	280
116	GIPC Is Recruited by APPL to Peripheral TrkA Endosomes and Regulates TrkA Trafficking and Signaling. <i>Molecular and Cellular Biology</i> , 2006, 26, 8942-8952.	1.1	124
117	Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. <i>Oncogene</i> , 2005, 24, 6080-6089.	2.6	153
118	Perturbations of the AKT signaling pathway in human cancer. <i>Oncogene</i> , 2005, 24, 7455-7464.	2.6	1,184
119	AKT signaling in normal and malignant cells. <i>Oncogene</i> , 2005, 24, 7391-7393.	2.6	252
120	A Mouse Model Recapitulating Molecular Features of Human Mesothelioma. <i>Cancer Research</i> , 2005, 65, 8090-8095.	0.4	152
121	The NF2 Tumor Suppressor Gene Product, Merlin, Inhibits Cell Proliferation and Cell Cycle Progression by Repressing Cyclin D1 Expression. <i>Molecular and Cellular Biology</i> , 2005, 25, 2384-2394.	1.1	155
122	Human Follicle-Stimulating Hormone (FSH) Receptor Interacts with the Adaptor Protein APPL1 in HEK 293 Cells: Potential Involvement of the PI3K Pathway in FSH Signaling ¹ . <i>Biology of Reproduction</i> , 2004, 71, 629-636.	1.2	104
123	Altered gene expression in phenotypically normal renal cells from carriers of tumor suppressor gene mutations. <i>Cancer Biology and Therapy</i> , 2004, 3, 1313-1321.	1.5	24
124	Tumor suppressor genes and the two-hit model of recessive oncogenesis: Celebrating Alfred Knudson's 80th birthday. <i>Genes Chromosomes and Cancer</i> , 2003, 38, 286-287.	1.5	7
125	p21-activated Kinase Links Rac/Cdc42 Signaling to Merlin. <i>Journal of Biological Chemistry</i> , 2002, 277, 883-886.	1.6	236
126	Detection of SV40 DNA sequences in malignant mesothelioma specimens from the United States, but not from Turkey. <i>Journal of Cellular Biochemistry</i> , 2002, 84, 455-459.	1.2	39

#	ARTICLE	IF	CITATIONS
127	Frequent activation of AKT2 kinase in human pancreatic carcinomas. <i>Journal of Cellular Biochemistry</i> , 2002, 87, 470-476.	1.2	131
128	Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey. <i>Lancet</i> , The, 2001, 357, 444-445.	6.3	250
129	Genomic imbalances in human lung adenocarcinomas and squamous cell carcinomas. <i>Genes Chromosomes and Cancer</i> , 2001, 31, 282-287.	1.5	101
130	Absence of post-transcriptional RNA modifications of BCL10 in human malignant mesothelioma and colorectal cancer. <i>Genes Chromosomes and Cancer</i> , 2001, 30, 96-98.	1.5	5
131	Human hepatocellular carcinoma is characterized by a highly consistent pattern of genomic imbalances, including frequent loss of 16q23.1-24.1. <i>Genes Chromosomes and Cancer</i> , 2001, 30, 245-253.	1.5	65
132	Loss of heterozygosity analysis defines a 3-cM region of 15q commonly deleted in human malignant mesothelioma. <i>Oncogene</i> , 2001, 20, 6245-6249.	2.6	20
133	Cyclin T2A Gene Maps on Human Chromosome 2q21. <i>Journal of Histochemistry and Cytochemistry</i> , 2001, 49, 693-697.	1.3	16
134	Loss of heterozygosity analysis of 13q and 14q in human malignant mesothelioma. <i>Genes Chromosomes and Cancer</i> , 2000, 28, 337-341.	1.5	27
135	Expression of GPC3, an X-linked recessive overgrowth gene, is silenced in malignant mesothelioma. <i>Oncogene</i> , 2000, 19, 410-416.	2.6	142
136	Loss of heterozygosity analysis of 13q and 14q in human malignant mesothelioma. , 2000, 28, 337.		1
137	Identification of a chromosome 3p14.3-21.1 gene, APPL, encoding an adaptor molecule that interacts with the oncoprotein-serine/threonine kinase AKT2. <i>Oncogene</i> , 1999, 18, 4891-4898.	2.6	190
138	Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma. , 1999, 180, 150-157.		139
139	Frequent mutations of NF2 and allelic loss from chromosome band 22q12 in malignant mesothelioma: Evidence for a two-hit mechanism of NF2 inactivation. <i>Genes Chromosomes and Cancer</i> , 1999, 24, 238-242.	1.5	97
140	A new human synovial sarcoma cell line, HS-SY-3, with a truncated form of hybrid SYT/SSX1 gene. , 1999, 82, 459-464.		23
141	Akt2 mRNA is highly expressed in embryonic brown fat and the AKT2 kinase is activated by insulin. <i>Oncogene</i> , 1998, 16, 2407-2411.	2.6	118
142	Translocation and activation of AKT2 in response to stimulation by insulin. <i>Journal of Cellular Biochemistry</i> , 1998, 70, 433-441.	1.2	28
143	Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. , 1998, 21, 81-86.		276
144	Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. , 1998, 21, 81.		2

#	ARTICLE	IF	CITATIONS
145	Identification of a zinc-finger gene at 6q25: a chromosomal region implicated in development of many solid tumors. <i>Oncogene</i> , 1997, 14, 1973-1979.	2.6	92
146	Transforming activity and mitosis-related expression of the AKT2 oncogene: evidence suggesting a link between cell cycle regulation and oncogenesis. <i>Oncogene</i> , 1997, 14, 2793-2801.	2.6	139
147	Association of Krev-1/rap1a with Krit1, a novel ankyrin repeat-containing protein encoded by a gene mapping to 7q21-22. <i>Oncogene</i> , 1997, 15, 1043-1049.	2.6	213
148	Detection of DNA gains and losses in primary endometrial carcinomas by comparative genomic hybridization. , 1997, 18, 115-125.		64
149	Combined chromosome microdissection and comparative genomic hybridization detect multiple sites of amplified DNA in a human lung carcinoma cell line. , 1997, 20, 208-212.		30
150	Comparative genomic hybridization detects frequent overrepresentation of chromosomal material from 3q26, 8q24, and 20q13 in human ovarian carcinomas. , 1997, 20, 320-328.		169
151	Detection of low-fraction K-ras mutations in primary lung tumors using a sensitive method. , 1997, 74, 162-170.		17
152	Comparative genomic hybridization detects frequent overrepresentation of chromosomal material from 3q26, 8q24, and 20q13 in human ovarian carcinomas. <i>Genes Chromosomes and Cancer</i> , 1997, 20, 320-328.	1.5	2
153	Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. <i>International Journal of Cancer</i> , 1995, 64, 280-285.	2.3	781
154	Deletion mapping of the short arm of chromosome 3 in human malignant mesothelioma. <i>Genes Chromosomes and Cancer</i> , 1994, 9, 76-80.	1.5	37
155	Cytogenetic analysis of 63 non-small cell lung carcinomas: Recurrent chromosome alterations amid frequent and widespread genomic upheaval. <i>Genes Chromosomes and Cancer</i> , 1994, 11, 178-194.	1.5	72
156	Cytogenetic abnormalities in non-small cell lung carcinoma: Similarity of findings in conventional and feeder cell layer cultures. <i>Genes Chromosomes and Cancer</i> , 1993, 6, 30-38.	1.5	6
157	Involvement of the RAF1 locus, at band 3p25, in the 3p deletion of small-cell lung cancer. <i>Genes Chromosomes and Cancer</i> , 1991, 3, 283-293.	1.5	36
158	Chromosome alterations in 21 non-small cell lung carcinomas. <i>Genes Chromosomes and Cancer</i> , 1990, 2, 328-338.	1.5	64
159	Recurring loss involving chromosomes 1, 3, and 22 in malignant mesothelioma: Possible sites of tumor suppressor genes. <i>Genes Chromosomes and Cancer</i> , 1989, 1, 148-154.	1.5	91
160	SV40 infection induces telomerase activity in human mesothelial cells. , 0, .		1
161	Akt1 and Akt2 Differently Regulate Muscle Creatine Kinase and Myogenin Gene Transcription in Insulin-Induced Differentiation of C2C12 Myoblasts. , 0, .		20